
    
      This is a randomized, double-blind, placebo-controlled, multicenter study of apalutamide plus
      GnRH agonist compared with GnRH agonist among participants with high-risk, localized or
      locally advanced prostate cancer receiving primary radiation therapy (RT). The study will
      include a Screening Phase, Treatment Phase, a Posttreatment Phase, and a Long-term Follow-up
      Phase. Participants will either receive either apalutamide (experimental) or bicalutamide 50
      milligram (mg) capsule plus placebo as control group. Safety will be monitored throughout the
      study.
    
  